Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Laboratory Biomarker Analysis

Related Conditions

Often studied with 15 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00454363Phase 2CompletedPrimary

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

NCT01204476Phase 1CompletedPrimary

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Showing all 2 trials

Research Network

Common Treatments

  • Laboratory Biomarker Analysis2
  • Pharmacological Study2
  • Cixutumumab1
  • Pazopanib Hydrochloride1
  • Octreotide Acetate1

Active Sponsors

  • National Cancer Institute (NCI)2

Top Investigators

Related Conditions

  • Lung Carcinoid Tumor2
  • Regional Digestive System Neuroendocrine Tumor G12
  • Pancreatic Glucagonoma2
  • Recurrent Digestive System Neuroendocrine Tumor G12
  • Somatostatinproducing Neuroendocrine Tumor2

Activity Timeline